Makers Laboratories Q1 Results: Profit up 244% in FY27

Introduction: what changed in Q1FY27

Makers Laboratories Limited has reported its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27), with the Board of Directors approving the numbers at a meeting held on August 7, 2026 in Mumbai. The headline number was a sharp improvement in consolidated profitability, even as the standalone pharmaceutical business remained under pressure. Consolidated net profit attributable to owners of the parent rose to ₹1.50 crore, compared with ₹0.44 crore a year earlier. Consolidated revenue from operations also increased year-on-year, supported by performance in the company’s Chemical Manufacturing segment. Alongside the results, the board disclosed a change in directorship involving CEO and Whole-time Director Saahil Parikh, effective August 11, 2026, subject to shareholder approval. The combination of improved consolidated earnings and a weaker standalone picture sets up a split narrative for investors tracking the company’s operating mix.

Consolidated performance: profit rises sharply

On a consolidated basis, Makers Laboratories reported net profit attributable to owners of ₹1.50 crore in Q1FY27. The comparable number in Q1FY26 was ₹0.44 crore, reflecting a strong year-on-year improvement. The company’s disclosure linked the improvement to stronger performance in the Chemical Manufacturing segment. While the consolidated numbers indicate better profitability, the underlying drivers matter because the standalone pharmaceutical business posted a loss over the same period. This divergence between consolidated and standalone outcomes suggests that non-pharma operations carried a larger share of earnings during the quarter. The results were reported as unaudited.

Revenue growth: year-on-year and sequential comparison

Consolidated revenue from operations rose to ₹42.77 crore in Q1FY27 from ₹35.00 crore in Q1FY26. The company also disclosed the immediately preceding quarter’s consolidated revenue from operations at ₹35.75 crore (Q4FY26). This places Q1FY27 not only higher year-on-year but also materially above the Q4FY26 base. The move in revenue is an important context point because it coincided with the jump in consolidated profit attributable to owners.

Standalone pharmaceutical business: losses widen

The standalone pharmaceutical business continued to report losses. For Q1FY27, the standalone business posted a net loss of ₹1.08 crore, widening from a net loss of ₹0.27 crore in Q1FY26. Revenue from operations in the standalone business declined to ₹10.19 crore, as per the disclosure. The wider loss alongside lower standalone revenue highlights the ongoing headwinds in the pharma-only view of the company’s performance during the quarter.

Segment detail: Chemical Manufacturing delivers higher PBT

Makers Laboratories highlighted the Chemical Manufacturing segment as a key support to the consolidated outcome. Segment profit before tax (PBT) for Chemical Manufacturing was reported at ₹7.55 crore for the quarter. This segment-level profitability is material relative to the consolidated net profit attributable to owners, and it helps explain why consolidated earnings improved even as the standalone pharma business remained loss-making. The disclosure did not provide additional segment-level breakup in the provided text beyond the Chemical Manufacturing PBT figure.

Key numbers table (normalised to ₹ crore)

All monetary amounts below are presented in ₹ crore for consistency.

Board meeting outcome and CEO transition

The board meeting that approved the Q1FY27 results also included a disclosure on management changes. Saahil Parikh (DIN 00400079) informed the board that he does not wish to be re-appointed as Whole-time Director and CEO when his term concludes on August 10, 2026, citing personal and professional reasons. He also confirmed that there were no other material reasons for the decision. The board appointed him as a Non-Executive, Non-Independent Director with effect from August 11, 2026, subject to shareholder approval. Such transitions are closely tracked by markets because they can influence execution priorities and oversight, particularly during periods when performance differs across business segments.

Revised board composition effective August 11, 2026

The company disclosed the revised board composition effective August 11, 2026 as follows.

Stock snapshot included in the provided data

The provided text also carried market data points, including that the stock is not traded on NSE. It showed “Today: 143.20” and a 52-week range of 109.00 to 186.70. A separate figure “147.00 1.40 (0.96%)” was also included in the text. These price indicators provide context around how the stock has been trading, although the results disclosure itself is focused on the quarter’s financial performance and the board-level changes.

Why the split performance matters for investors

The Q1FY27 update is notable because it shows two different pictures depending on how the company is viewed. Consolidated results point to improved profitability and stronger revenue, supported by Chemical Manufacturing performance and a reported segment PBT of ₹7.55 crore. In contrast, the standalone pharmaceutical business posted a wider loss and lower revenue from operations. For investors, this places emphasis on understanding the relative contribution of business segments within the consolidated structure and how sustainable the earnings mix is across quarters.

What to watch next

The company has stated that Saahil Parikh’s appointment as a Non-Executive, Non-Independent Director from August 11, 2026 is subject to shareholder approval. Any subsequent disclosures around leadership responsibilities, operational priorities, or further segment-level performance details will be important for assessing the balance between consolidated profitability and the standalone pharma trajectory. The next set of quarterly results should also clarify whether the consolidated revenue step-up in Q1FY27 sustains and whether the standalone loss trend shows signs of stabilisation.